Dosing and Regimen Changes Promote Tolerability in Advanced Melanoma
Source: Targeted Oncology, March 2024
During a Targeted Oncology™ Case-Based Roundtable™ event, Michael B. Atkins, MD, discussed dosing considerations and toxicity when choosing combination treatment for patients with melanoma. This is the second of 2 articles based on this event.
DISCUSSION QUESTIONS
- Are you familiar with the RELATIVITY-047 (NCT03470922) data on nivolumab plus relatlimab (Opdualag) vs nivolumab (Opdivo) alone?
- What are your reactions to these data?
TARAL PATEL, MD: I am familiar with the data, but…50% of patients may [have] prolonged remissions…with ipilimumab [Yervoy] plus nivolumab, so how we can follow 2- to 3-year data and change the standard of care?1 That’s my biggest obstacle to changing the treatment options.